异动解读 | 新股热潮持续，MIRXES-B上市首日大涨33.26%

异动解读2025-05-23

今日盘中，新上市公司MIRXES-B（02629）股价大涨33.26%，延续了近期港股新股上市的强劲表现。MIRXES-B是一家总部位于新加坡的微小核糖核酸(miRNA)技术公司，专注于癌症及其他疾病的早期检测技术。

MIRXES-B此次全球发售4662万股，每股发售价23.3港元，募集资金净额约8.8亿港元。公司香港公开发售部分获得25.51倍超额认购，显示出投资者对其发展前景的看好。然而值得注意的是，MIRXES-B目前仍处于亏损状态，2024年亏损达0.92亿美元。

分析人士指出，MIRXES-B股价的强劲表现反映了市场对生物科技和早期疾病检测领域的高度关注。与此同时，今日同步上市的恒瑞医药也录得可观涨幅，进一步印证了港股市场近期新股上市普遍表现强劲的趋势。不过，投资者仍需谨慎关注公司的盈利能力和长期发展前景。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1109074535?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-23 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109074535","market":"sg","top_or_hot":-1,"title":"异动解读 | 新股热潮持续，MIRXES-B上市首日大涨33.26%","media":"异动解读","content":"<p>今日盘中，新上市公司MIRXES-B（02629）股价大涨33.26%，延续了近期港股新股上市的强劲表现。MIRXES-B是一家总部位于新加坡的微小核糖核酸(miRNA)技术公司，专注于癌症及其他疾病的早期检测技术。</p>\n\n<p>MIRXES-B此次全球发售4662万股，每股发售价23.3港元，募集资金净额约8.8亿港元。公司香港公开发售部分获得25.51倍超额认购，显示出投资者对其发展前景的看好。然而值得注意的是，MIRXES-B目前仍处于亏损状态，2024年亏损达0.92亿美元。</p>\n\n<p>分析人士指出，MIRXES-B股价的强劲表现反映了市场对生物科技和早期疾病检测领域的高度关注。与此同时，今日同步上市的恒瑞医药也录得可观涨幅，进一步印证了港股市场近期新股上市普遍表现强劲的趋势。不过，投资者仍需谨慎关注公司的盈利能力和长期发展前景。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 新股热潮持续，MIRXES-B上市首日大涨33.26%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 新股热潮持续，MIRXES-B上市首日大涨33.26%\n</h2>\n\n<h4 class=\"meta\">\n\n2025-05-23 09:32 北京时间&nbsp;&nbsp;&nbsp;<strong>异动解读</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>今日盘中，新上市公司MIRXES-B（02629）股价大涨33.26%，延续了近期港股新股上市的强劲表现。MIRXES-B是一家总部位于新加坡的微小核糖核酸(miRNA)技术公司，专注于癌症及其他疾病的早期检测技术。\nMIRXES-B此次全球发售4662万股，每股发售价23.3港元，募集资金净额约8.8亿港元。公司香港公开发售部分获得25.51倍超额认购，显示出投资者对其发展前景的看好。然而...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02629","symbol_name":"MIRXES-B","start_time":0,"source_url":"","article_id":"1109074535","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109074535","pubTimestamp":1747963967,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"今日盘中，新上市公司MIRXES-B股价大涨33.26%，延续了近期港股新股上市的强劲表现。MIRXES-B是一家总部位于新加坡的微小核糖核酸技术公司，专注于癌症及其他疾病的早期检测技术。MIRXES-B此次全球发售4662万股，每股发售价23.3港元，募集资金净额约8.8亿港元。然而值得注意的是，MIRXES-B目前仍处于亏损状态，2024年亏损达0.92亿美元。分析人士指出，MIRXES-B股价的强劲表现反映了市场对生物科技和早期疾病检测领域的高度关注。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02629":"MIRXES-B"},"translate_title":"Interpretation of changes: The upsurge of new stocks continues, MIRXES-B rose 33.26% on the first day of listing","themeId":"4ced5ebc15dd7b799c1c8ea5b39c4a94","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02629":1},"content_text":"今日盘中，新上市公司MIRXES-B（02629）股价大涨33.26%，延续了近期港股新股上市的强劲表现。MIRXES-B是一家总部位于新加坡的微小核糖核酸(miRNA)技术公司，专注于癌症及其他疾病的早期检测技术。\nMIRXES-B此次全球发售4662万股，每股发售价23.3港元，募集资金净额约8.8亿港元。公司香港公开发售部分获得25.51倍超额认购，显示出投资者对其发展前景的看好。然而值得注意的是，MIRXES-B目前仍处于亏损状态，2024年亏损达0.92亿美元。\n分析人士指出，MIRXES-B股价的强劲表现反映了市场对生物科技和早期疾病检测领域的高度关注。与此同时，今日同步上市的恒瑞医药也录得可观涨幅，进一步印证了港股市场近期新股上市普遍表现强劲的趋势。不过，投资者仍需谨慎关注公司的盈利能力和长期发展前景。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109074535","isCrawlerRequest":true}